Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines, today
announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head
of Research & Development, Ocugen will speak at the Retina
World Congress (RWC) being held May 9-12, 2024 in Ft. Lauderdale,
FL.
“This is a terrific opportunity to share the most recent
developments in modifier gene therapy with my peers and learn more
about their discoveries to fight retinal disease,” said Dr.
Upadhyay. “Opportunities like these are critical as we work
together to address unmet medical needs for patients with blindness
diseases.”
RWC is one of the largest retina meetings in the world and is
leading the advancement of science in retina. This annual meeting
brings together retina specialists from every continent to achieve
a global scientific and clinical exchange in retinal
health.
Details on Dr. Upadhyay’s presentation are as follows:
RWC Unplugged Panel Session: Gene Therapy,
Pharmacotherapy and Optogenetics for IRDDate:
Thursday, May 9, 2024Time: 9:05 – 9:35 a.m. (ET)
Location: Marriott Harbor Beach Resort
Additionally, Ocugen’s abstract, "Safety and Efficacy Results
from a Phase 1/2 Clinical Trial of OCU400 Modifier Gene Therapy for
Treatment of Retinitis Pigmentosa," has been accepted as an
e-poster/video presentation and will be showcased in a video
display during the conference.
The OCU400 Phase 3 liMeliGhT clinical trial is currently
underway and on track to meet the Company’s 2026 BLA and MAA
approval targets. OCU400 is the first gene therapy program to enter
Phase 3 with a broad retinitis pigmentosa (RP) indication.
About OCU400OCU400 is the Company’s
gene-agnostic modifier gene therapy product based on nuclear
hormone receptor (NHR) gene, NR2E3. NR2E3 regulates
diverse physiological functions within the retina—such as
photoreceptor development and maintenance, metabolism,
phototransduction, inflammation and cell survival networks. Through
its drive functionality, OCU400 resets altered/affected cellular
gene networks and establishes homeostasis—a state of balance, which
has the potential to improve retinal health and function in
patients with RP. Between the U.S. and EU, nearly 300,000 people
are affected by RP.
About Modifier Gene TherapyModifier
gene therapy is designed to fulfill unmet medical needs related to
retinal diseases, including IRDs, such as RP, Leber congenital
amaurosis and Stargardt disease, as well as multifactorial diseases
like dry age-related macular degeneration (dAMD). Our modifier gene
therapy platform is based on the use of NHRs, master gene
regulators, which have the potential to restore homeostasis — the
basic biological processes in the retina. Unlike single-gene
replacement therapies, which only target one genetic mutation, we
believe that our modifier gene therapy platform, through its use of
NHRs, represents a novel approach that has the potential to address
multiple retinal diseases caused by mutations in multiple genes
with one product, and to address complex diseases that are
potentially caused by imbalances in multiple gene networks.
Currently, Ocugen has three modifier gene therapy programs in the
clinic: OCU400, OCU410, and OCU410ST. In addition to the OCU400
Phase 3 liMeliGhT clinical trial, the OCU410 Phase 1/2 ArMaDa
clinical trial for geographic atrophy (GA) secondary to dAMD and
the OCU410ST Phase 1/2 GARDian clinical trial for Stargardt disease
are currently underway. GA affects approximately two to three
million people between the U.S. and EU and Stargardt disease
affects nearly 100,000 people between the U.S. and EU.
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines that
improve health and offer hope for patients across the globe. We are
making an impact on patient’s lives through courageous
innovation—forging new scientific paths that harness our unique
intellectual and human capital. Our breakthrough modifier gene
therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on X and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
regarding qualitative assessments of available data, potential
benefits, expectations for ongoing clinical trials, anticipated
regulatory filings and anticipated development timelines, which are
subject to risks and uncertainties. We may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” or other
words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks, and uncertainties
that may cause actual events or results to differ materially from
our current expectations, including, but not limited to, the risks
that preliminary, interim and top-line clinical trial results may
not be indicative of, and may differ from, final clinical data;
that unfavorable new clinical trial data may emerge in ongoing
clinical trials or through further analyses of existing clinical
trial data; that earlier non-clinical and clinical data and testing
of may not be predictive of the results or success of later
clinical trials; and that that clinical trial data are subject to
differing interpretations and assessments, including by regulatory
authorities. These and other risks and uncertainties are more fully
described in our periodic filings with the Securities and Exchange
Commission (SEC), including the risk factors described in the
section entitled “Risk Factors” in the quarterly and annual reports
that we file with the SEC. Any forward-looking statements that we
make in this press release speak only as of the date of this press
release. Except as required by law, we assume no obligation to
update forward-looking statements contained in this press release
whether as a result of new information, future events, or
otherwise, after the date of this press release.
Contact:Tiffany HamiltonHead of
CommunicationsTiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Oct 2023 to Oct 2024